Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction?
about
Leukoreduction for the prevention of adverse reactions from allogeneic blood transfusionLeukoreduction for the prevention of adverse reactions from allogeneic blood transfusionAnti-fibrinolytic use for minimising perioperative allogeneic blood transfusionImpact of blood transfusions on patients with head and neck cancer undergoing free tissue transfer.Totally laparoscopic versus conventional ileoanal pouch procedure--design of a single-centre, expertise based randomised controlled trial to compare the laparoscopic and conventional surgical approach in patients undergoing primary elective restoratTransfusion-related risks of intradermal allogeneic lymphocyte immunotherapy: single cases in a large cohort and review of the literature.Cancer risk among 21st century blood transfusion recipients.Leukoreduced blood components: Advantages and strategies for its implementation in developing countries.Universal WBC reduction: the case for and against.Effects of transfusion with red cells filtered to remove leucocytes: randomised controlled trial in patients undergoing major surgeryEvidence-based recommendations for the use of WBC-reduced cellular blood components.Pharmacotherapy of anaemia in cancer patients.Mirasol PRT treatment of donor white blood cells prevents the development of xenogeneic graft-versus-host disease in Rag2-/-gamma c-/- double knockout mice.The intention-to-treat principle in clinical trials and meta-analyses of leukoreduced blood transfusions in surgical patients.Biology of anemia, differential diagnosis, and treatment options in human immunodeficiency virus infection.The impact of prolonged storage of red blood cells on cancer survival.Longer RBC storage duration is associated with increased postoperative infections in pediatric cardiac surgeryA comprehensive assessment of transfusion in elective pancreatectomy: risk factors and complications.Absence of transfusion-associated microchimerism in pediatric and adult recipients of leukoreduced and gamma-irradiated blood components.Transfusion of post-operative shed blood: laboratory characteristics and clinical utility.The safety and efficacy of "bloodless" cardiac surgery.Deleterious clinical effects of transfusion immunomodulation: proven beyond a reasonable doubt.Control of immune responses induced by the transfer of allogeneic white blood cells during transfusion.Transfusion immunomodulation or TRIM: what does it mean clinically?Red blood cell transfusions and the risk of acute respiratory distress syndrome among the critically ill: a cohort study.Perioperative transfusion for pancreaticoduodenectomy and its impact on prognosis in resected pancreatic ductal adenocarcinoma.The influence of allogenic blood transfusion in patients having free-flap primary surgery for oral and oropharyngeal squamous cell carcinoma.Genetic polymorphisms in IL10RA and TNF modify the association between blood transfusion and risk of non-Hodgkin lymphomaPredeposit autologous donation in spinal surgery: a multicentre study.Impact of blood transfusions on survival and recurrence in colorectal cancer surgery.Bloodless (liver) surgery? The anesthetist's view.Why have meta-analyses of randomized controlled trials of the association between non-white-blood-cell-reduced allogeneic blood transfusion and postoperative infection produced discordant results?Preoperative autologous blood donation reduces the need for allogeneic blood products: a prospective randomized study.Red Blood Cell Transfusions Impact Pneumonia Rates After Coronary Artery Bypass Grafting.Blood transfusion promotes cancer progression: a critical role for aged erythrocytes.Washing red blood cells and platelets transfused in cardiac surgery reduces postoperative inflammation and number of transfusions: results of a prospective, randomized, controlled clinical trialIron deficiency or anemia of inflammation? : Differential diagnosis and mechanisms of anemia of inflammationBlood transfusion for the treatment of acute anaemia in inflammatory bowel disease and other digestive diseases.Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT.Blood transfusion, anesthesia, surgery and risk of non-Hodgkin lymphoma in a population-based case-control study.
P2860
Q24187243-0D011349-1D9C-42F9-AD53-D0A7A0BCB63CQ24201602-013B04E9-B980-44FF-B177-606AF163C925Q24235627-2DA2C05B-EF82-474F-8A98-680600CCFA88Q30458885-69B25581-AFFF-4610-88A7-49F8ECBD1A96Q33264583-BE37335D-5B5B-4C7A-A93E-CD55C332C5DCQ33372263-D362BE71-1701-4411-BADD-3D2CA79495DCQ33564734-0205289B-5AC8-4C56-AEF8-F10CA253E5A4Q33760699-0C7D23B9-C44D-451F-B753-EF54D7EECBB7Q34247853-8F439A5C-D4EC-4BE5-9E82-59EB715053C6Q34362686-E3259225-5EA9-4AE5-9682-D0A5D99B8649Q34405086-7EE9E8C5-EAB8-400A-864D-5B5E9A6194C9Q34515556-76944308-383D-4919-AD03-5C0F5D37D072Q34565186-E8F47D5C-C37D-40A0-BE2F-C87B218540E1Q34611743-FBA17BC9-E723-4DA7-8712-63D93832358FQ34631656-71E68182-DC0C-435D-A044-3416386DA1A4Q34851314-A44A2F77-52E3-4D09-8C49-AB5E746805DEQ35152059-1C58BCCD-303B-4274-914C-25ACE309A9EFQ35297820-7C26701F-363D-4910-8ABC-C3ED230360C3Q35670166-2BA2EFA0-E7B8-4A2A-BAC6-8171EFF4899DQ35771021-431A67CB-5062-4CFD-B4C1-3A761A4D70B8Q36056765-AC8E38FB-C06B-4E98-933B-804DA9FD497BQ36222164-AD77CBE5-503A-43BE-A87F-7D6CCCFDBDD8Q36222170-6EEB62BC-4470-4F84-9E01-8583D511D955Q36270091-CE2F018A-5DEA-4456-B07A-F11C3017EEFDQ36392495-D71F3D2A-22B9-47B3-81C1-FB7F4A5C4586Q36408362-68E0A6B5-7DFF-47A3-AAA8-F860187B7CA3Q36613935-A33210CC-D43F-4AE9-B619-7ED1C4901818Q36622888-2BC0FF4D-4A35-462B-9CCC-210BE6C67D6DQ36668036-66365220-41CB-446E-AB3B-1BF650F1FF9FQ36815746-E45FA4B6-68BF-44D1-8C63-AE7F8FD0427FQ36893494-0D693961-7073-4052-B6FD-8C9B5C93554BQ36936374-9044D54E-05B9-4192-9D07-8C1616D4C8F5Q36992721-408E29BA-4521-4F2A-B508-638EEDA2F559Q36996206-5BF81E8E-8D2F-45AA-B2E5-9DB2EC4DC26EQ37223763-81003A42-E869-4DFF-84C1-B4C1669E7603Q37341042-5E7608B6-B55A-44B3-AB13-6690019CC6B9Q37341829-FDA82A66-E486-4AC8-ADF6-F0AAAA15DF57Q37368736-F9CA82B8-0C52-4695-B932-35590EC36741Q37389675-9FB0157E-08DF-4EEC-B963-887D21F62C76Q37553827-AF8FDAF4-227E-4679-9140-0AF60E152DE3
P2860
Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction?
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction?
@ast
Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction?
@en
Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction?
@nl
type
label
Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction?
@ast
Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction?
@en
Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction?
@nl
prefLabel
Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction?
@ast
Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction?
@en
Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction?
@nl
P356
P1433
P1476
Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction?
@en
P2093
Blajchman MA
Vamvakas EC
P304
P356
10.1182/BLOOD.V97.5.1180
P407
P577
2001-03-01T00:00:00Z